Outcome prediction in cancer is usually achieved by evaluating tissue samples obtained during surgical removal of a primary tumor, and focusing on the histopathological characteristics. Tumor staging (AJCC/UICC-TNM classification) is based on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N), and evidence of metastases (M). However, cancer outcomes can differ significantly between patients whose cancers are at the same stage. The TNM classification provides limited prognostic information in cancer and does not predict response to therapy.
Increasingly, data suggest that cancer development is controlled by the host’s immune system, underlying the importance of including immunological biomarkers in the determination of prognosis and response to therapy, a concept that has been termed “immunoscore”. Data collected from human cancer tissue samples demonstrate that immune classification has prognostic value and may be a useful supplement to the AJCC/UICC TNM-classification. It is therefore important to begin incorporating immune scoring in determinations of cancer prognosis, and to make sure it becomes a routine part of the diagnostic and prognostic assessment of patients with cancer.
At the same time, the complexity of quantitative immunohistochemistry, and the variable assay protocols, immune cell types analyzed, tumor sampling criteria, and ways in which immune infiltration is quantified in different laboratories underscore the need to harmonize immune assays.
In an effort to promote use of the immunoscore in routine clinical settings, the SITC Immunoscore Validation Project was initiated with 23 centers in 17 countries worldwide (click image to right). This project was organized in collaboration with the European Academy of Tumor Immunology; the Cancer and Inflammation Program; the National Cancer Institute, National Institutes of Health, USA; and La Fondazione Melanoma, Italy. The results of this global validation project may result in implementation of the immunoscore as a new component in the classification of cancer.
In order to help move the Immunoscore assay into the clinic and ultimately to benefit patients with cancer, SITC is pleased to announce a Key Information Release from the SITC Immunoscore Validation Project. Under this release, key information concerning the detailed methodology used to calculate the Immunoscore will be shared to qualified entities upon request. To learn more about the Key Information Release, review criteria, and application process, please visit here. Information Request Forms deadline was July 5, 2016.
The latest results from the Immunoscore project were presented by Dr. Jérôme Galon during the Oral Abstract Session at the 2016 ASCO Annual Meeting in June 2016. To view the SITC press release and updated results, click here.
In the video below, published by OncLive, watch as past SITC President Dr. Bernard Fox explains the significance of Immunoscore Validation.
Bernard A. Fox, PhDEarle A. Chiles Research Institute
Paolo Ascierto, MDInstituto Nazionale Tumori-Fondazione 'G. Pascale'
Carlo Bifulco, MDProvidence Portland Medical Center
Jérôme Galon, PhDInserm, Cordeliers Research Center
Francesco Marincola, MDSidra Medical and Research Center
Jérôme Galon, PhDINSERM, Cordeliers Research Center, Paris, France
Franck Pagès, MD, PhDImmunomonitoring plateform, Georges Pompidou European Hospital, Paris, France INSERM, Cordeliers Research Center, Paris, France
Melanoma Bridge 2015 December 1-4, 2015 – Naples, Italy World-Wide Immunoscore Task Force: an Update For more information, visit here.
Immunoscore Update Session at the STIC 30th Annual Meeting November 7, 2015 – National Harbor, MD View video and presentation slides from this program here.
Immunoscore Slide Sharing Portal kick-off call and PathForceDx online training session August 13, 2014 Participating Centers from across Europe, Asia, and North America met online to explore PathForceDx software functions and to discuss ideas and best practices for sharing slides and data.
Natural and Therapy-induced Anticancer Immunosurveillance: The Immunoscore July 3-4, 2014 – Paris, France
Updates on Immunotherapy of Cancer and Immunoscore January 23-24, 2014 – Doha, Qatar View abstracts published in JITC.
World Immunoscoring Meeting December 4, 2012 – Naples, Italy Supported by SITC, Melanoma Foundation and EATI
This initiative has been made possible by the generous support of the following companies:
Slide-sharing portal powered by PathForceDX.
Be Part of the Breakthrough at the Charles River World Congress on Animal Models in Drug Discovery & Development. Boston | September 26-27, 2017 http://breakthroughs.criver.com/index.html
Use of mAb-based immunotherapies has resulted in major improvements in treatment of B-cell neoplasms, but patients can relapse, succumbing to the disease. An alternative approach that destroys tumor cells including cancer stem cells is, thus, needed urgently. ...
According to the cited pharma company document within, out of Hemel Hempstead, England, May 10, 2017, Dinutuximab beta, originally developed by the Vienna-based biotech company Apeiron Biologics for neuroblastoma, was previously available in Europe under ...
The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients. In this exclusive interview with Oncology Central, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org